Semglee has been approved for over a year as a regular biosimilar to Lantus (insulin glargine), meaning that it could be used in place of Sanofi's drug, but only if specifically prescribed for a ...

For instance, the European Medicines Agency (EMA) approved Biocon's insulin glargine biosimilar, Semglee, in September 2023 for the treatment of diabetes. By type of insulin, the long-acting ...